EIPC Workshop on PCB BioMEMS


Reading time ( words)

The Premier Inn conference centre at Heathrow Airport was the venue for the EIPC workshop on PCB BioMEMS. What, I hear you ask, is a PCB BioMEMS? This is an abbreviation for biomedical (or biological) microelectromechanical systems, otherwise known as lab-on-chip.

Given the strong market pull for more BioMEMS devices (USD $2.5 billion in 2014 and anticipated to grow at CAGR of more than 25% from 2016 to 2023), the commercialization of lab-on-chip devices is currently the Holy Grail of the research community. The lab-on-PCB approach (aka PCB BioMEMS) is being followed in various research groups all over Europe, owing to its inherent upscaling potential: the PCB industry is well-established all around the world, with standardized fabrication facilities and processes is currently commercially exploited only for electronics.

The workshop began with an introduction from Dr. Despina Moschou, 50th Anniversary Prize Fellow/Lecturer at the Centre for Advanced Sensor Technologies at the University of Bath. It was Despina who first introduced the concept of PCB BioMEMS to the EIPC at its Summer Conference in Edinburgh in June 2016, which ignited interest. She asked why lab-on-chip is not already more established using PCB technologies to provide the needed integration between the microfluidics, the biological elements and the electronics required to form an analytical system highlighting the long-standing industrial infrastructure, microfabrication capabilities and intuitive integration of electronics.

The first speaker was Dr. Yuksel Temiz of IBM’s Zurich Research Laboratory. Dr. Temiz explained that although there are over 1,400+ infectious species and 347 significant diseases, less than 5% of their prevalence has been accurately mapped. He postulated that the use of IoT-based devices linked to Smartphones or a handheld reader could revolutionise infectious disease mapping. He contrasted conventional lateral  flow technology, such as that used in pregnancy detectors noting that microfluidics technology would require a much smaller sample size and optimised flow control to give much better quantitative results when used in a portable immunodiagnostic microfluidic platform.

To read the full version of this article which appeared in the February 2017 issue of The PCB Magazine, click here.

Share

Print


Suggested Items

IPC Workforce Pledge Draws White House Praise, Points the Way to Jobs of the Future

11/09/2018 | Dr. John Mitchell, IPC
President Trump kicked off the workforce challenge to U.S. businesses in July. As a longtime leader in education and training within the electronics industry, IPC took it as an opportunity to review our existing programs and identify ways to grow and innovate. The result? IPC joined the Pledge to America’s Workers by promising to create new career opportunities for at least 1 million Americans in the electronics industry.

GP Ventures’ Tom Kastner on PCB Mergers and Acquisitions

10/10/2018 | Dan Beaulieu, D.B. Management Group
Tom Kastner, president of GP Ventures, he has his finger on the pulse of the industry's mergers and acquisitions (M&A) more than anyone. In this interview, Kastner provides insights on the right time to buy, how to evaluate your company's worth, and when it is too late.

Cerambus Discusses the Next Generation in PCB Plating

07/12/2018 | Stephen Las Marias, I-Connect007
Cerambus Technology Inc. President John Nash sat down with I-Connect007 for a discussion on the latest developments in plating technology, challenges and opportunities in the China market, and their strategy for sustaining growth in a highly competitive industry.



Copyright © 2018 I-Connect007. All rights reserved.